Effect of interventions during acute respiratory syncytial virus bronchiolitis on subsequent long term respiratory morbidity

Pediatric Infectious Disease Journal

Volumn 21, Issue 5, 2002, Pages 468-472

  Khoshoo, Vikram ^a   Ross, Gerald ^a   Edell, Dean ^a  

^a NONE   (United States)

Author keywords

Bronchiolitis; Long term respiratory morbidity; Respiratory syncytial virus; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; MONTELUKAST; PLACEBO; PREDNISOLONE; RIBAVIRIN; SALBUTAMOL; ACETIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ASPIRATION PNEUMONIA; BRONCHIOLITIS; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG RESEARCH; FOLLOW UP; HUMAN; MEDICAL LITERATURE; METHODOLOGY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; ACUTE DISEASE; INFANT; INFANT WELFARE; MORBIDITY; NEWBORN; PROSPECTIVE STUDY; REVIEW; VIRAL BRONCHIOLITIS; VIRUS INFECTION;

ACETATES; ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; BRONCHIOLITIS, VIRAL; CROMOLYN SODIUM; HUMAN; INFANT; INFANT WELFARE; INFANT, NEWBORN; LEUKOTRIENE ANTAGONISTS; MORBIDITY; PROSPECTIVE STUDIES; QUINOLINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; HUMANS;

EID: 0035999359     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200205000-00035     Document Type: Conference Paper

References (34)

1. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
2. Sequelae of respiratory syncytial virus infections: A role of intervention studies
3. Respiratory syncytial virus-induced chemokine expression in the lower airways: Eosinophil recruitment and degranulation
4. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease
5. Ribavirin suppresses pro-inflammatory cytokine production in pulmonary epithelial cells infected with respiratory syncytial virus
6. Interleukin 4, but not interleukin 5 or eosinophil is required in a murine model of acute airway hyper-reactivity
7. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
8. Ribavirin inhibits mast cell mediator release
9. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: Potential effect of ribavirin on long-term pulmonary function
10. Reduced long-term morbidity after treatment of respiratory syncytial virus bronchiolitis with and without ribavirin in previously healthy infants
11. Long-term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo
12. Prospective follow-up and pulmonary function from a place-bo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis
13. Effects of ribavirin therapy on RSV infections in high-risk infants and young children 2 years after hospitalization
14. Longitudinal pulmonary function following treatment with ribavirin in infants hospitalized with RSV bronchiolitis
15. Bronchial reactivity 8-15 years after respiratory syncytial virus lower respiratory tract infection
16. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis
17. Aspiration: A factor in rapidly deteriorating bronchiolitis in previously healthy infants?
18. Effect of aspiration of milk on mechanisms of neural control in the airway of developing rabbits
19. Airway reactivity following repeated aspiration in rabbits
20. Benefits of thickened feeds in previously healthy infants with respiratory syncytial viral bronchiolitis
21. Early ribavirin treatment of bronchiolitis: Effect on long-term respiratory morbidity
22. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody and glucocorticosteroid
23. The effect of flutcasone propionate on respiratory syncytial virus-induced chemokine release by a human bronchial epithelial cell line
24. Corticosteroids do not affect the clinical outcome or physiological status of infants with bronchiolitis
25. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus
26. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of post-bronchiolitic wheezing
27. Randomized placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis
28. Randomized controlled trial of budesonide for the prevention cf post bronchiolitis wheezing
29. No objective benefit from steroid inhaled via a spacer in infants recovering from bronchiolitis
30. Inhaled corticosteroid and wheezing post-bronchiolitis
31. Inhaled corticosteroids during and after respiratory syncytial virus bronchiolitis may decrease subsequent asthma
32. Anti-inflammatory therapy reduces wheezing after bronchiolitis
33. Montel ukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma
34. Use of montelukast in the treatment of early childhood wheezing from clinical experience with three cases